Preliminary dinical trial resuhs of CD19/CD22 targeted CARs for treatment of ALL/DLBCL and CD19/BCMA targeted for multiple myeloma have demonstrated promising efficacy*'. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.